TY - JOUR
T1 - Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination
T2 - Up to 6 months cross-sectional study
AU - Achiron, Anat
AU - Mandel, Mathilda
AU - Dreyer-Alster, Sapir
AU - Harari, Gil
AU - Dolev, Mark
AU - Menascu, Shay
AU - Magalashvili, David
AU - Flechter, Shlomo
AU - Givon, Uri
AU - Guber, Diana
AU - Sonis, Polina
AU - Zilkha-Falb, Rina
AU - Gurevich, Michael
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12/15
Y1 - 2021/12/15
N2 - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.
AB - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.
KW - COVID-19
KW - Disease modifying treatments
KW - Humoral immunity
KW - IgG antibody
KW - Multiple sclerosis
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85116922368&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2021.577746
DO - 10.1016/j.jneuroim.2021.577746
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34655991
AN - SCOPUS:85116922368
SN - 0165-5728
VL - 361
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
M1 - 577746
ER -